Immunofluorescence Assay Market Size, Share, Report 2022-2030

According to Vision Research Reports, the global immunofluorescence assay market size is expected to surpass around USD 4.61 billion by 2030, poised to grow at a CAGR of 6.8% from 2022 to 2030.

Immunofluorescence assay is a technique used in virology for the detection of antibodies by its selective ability to react with the antigen present in the infected cell. For this purpose, fluorescent dyes are used. It is one of the applied techniques of light microscopy. The results obtained from the techniques of ELISA and MFIA are confirmed using immunofluorescence assay (IFA). The technique is applied to specific sections of tissues, cells, and cell line cultures. It is used to analyze small molecules, proteins, and glycan’s. The requirements of the assay are a reagent kit, antibodies specific to antigens, imaging equipment and assay kit.

Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/39765

Scope of The Report

The two classes of immunofluorescence are as follows -

• Primary or direct immunofluorescence - Uses a single antibody linked to fluorophore detected using fluorescent microscopy. It is used to diagnose skin, and kidney diseases. Example- Lupus erythematosus disease diagnosis.
• Secondary or indirect immunofluorescence - Uses two antibodies. In this, the primary antibody binds the target molecule, and secondary antibody is linked to a fluorophore. It is used to diagnose autoimmune blister skin diseases. Example- Pemphigoid gestationis disease diagnosis. 

Over the last few decades, the prevalence of chronic disease like Chron’s disease, HIV, and Alzheimer’s has increased globally. A growing awareness regarding the detection and cure to these diseases are some of the driving factors for market growth. The major applications of immunofluorescence assay are antibody detection, antigen detection in cell culture and membranes, biopsy, and detection of spread immune cells, for example- Secondary (Indirect) Immunofluorescence Assay is used for detection of anticell membrane associated DNA Abs in juvenile systemic lupus erythematosus. In this Anti-cmDNA Abs and antinuclear Abs were detected in the patient serum using immunofluorescence and ELISA. Recently in April 2021, a company named Euroimmum launched a compact immunofluorescence microscope EPML (EUROPattern Microscope Live). EPML is an automated instrument that captures the image within 2 seconds. It has a 20x high camera resolution. 

In IFA, the imaging equipment are used to detect the fluorescently linked antibodies in the sample. These instruments are quite advanced in features and expensive. So this can be a restraining factor for the market. Due to the increasing prevalence of the autoimmune diseases, chronic diseases, it takes maximum expenditure of healthcare and research services. The health insurance and growing medical reimbursement has a positive impact on the growing IFA market. However, increasing government funding in research services and surgical research services will boost the market. 

The immunofluorescence assay market is segmented into type, product, application, end-user and region. The type segment is further bifurcated into direct immunofluorescence, and indirect immunofluorescence. The product segment is divided into antibodies, reagents, kits, instruments, consumables and accessories. The application segment is based upon autoimmune diseases, neurological diseases, clinical research and diagnostics, cardiovascular diseases and cancer. The end -user segment is based upon pharmaceutical and biotechnology companies, contract research organizations, hospitals and diagnostic centers. The region segment is further segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa.

The increasing prevalence of chronic diseases and infectious diseases is found to be the highest in North America and holds the highest share in the assay market. Moreover, the research is also supported through government funding and also developing the healthcare services that accelerates the market growth. Countries like India, China, and Brazil are expected to show a potential growth in the market in the near future. According to the research, India and China have a higher prevalence rate to diabetes that would boost the market. Middle East and Africa holds the least market share due to strict government policies, and poor economic development.

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39765

Key Highlights:

• Kits segment is expected to account for largest revenue share in the global market over the forecast period owing to increasing demand for complete solutions, calibrated reagents and controls from pharmaceutical and biotechnology companies, and CROs.
• Indirect immunofluorescence segment is expected to register fastest revenue growth during the forecast period attributable to numerous advantages offered by the technique such as improved flexibility, sensitivity, and improved signal amplification. This technique is more cost-effective as compared to direct immunofluorescence and is also expected to drive revenue growth of this segment over the forecast period.
• Cancer segment is expected to register significant revenue growth over the forecast period attributable to high prevalence of cancer worldwide, growing healthcare burden, and increasing adoption of immunofluorescence assays in screening and diagnosis of cancer.
• Pharmaceutical and biotechnology companies segment is expected to account for a robust revenue share in the global market owing to increasing use of immunofluorescence assays in antibodies-based therapeutics research and drug discovery and development processes.
• The market in North America is expected to account for largest revenue share during the forecast period owing to increasing healthcare burden of chronic and infectious diseases, advancements in drug discovery and research, rising funding by government and other organizations, and availability of favorable reimbursement policies.
• Prominent companies in the market include Thermo Fisher Scientific, Inc., Merck KGaA, Danaher Corporation, Abcam Plc, Bio-Rad Laboratories, Inc., PerkinElmer Inc., Werfen Company, Agilent Technologies, Cell Signaling Technology, Inc., MEDIPAN GmbH, Enzo Biochem, Inc., Becton, Dickinson and Company, Bruker Corporation, and EpiGentek Group, and others.
• In July 2020, Ultivue, Inc. and OracleBio joined forces in a bid to accelerate personalized tumor characterization for drug research and development by using multiplex immunofluorescence staining and imaging.

Key Players

• Thermo Fisher Scientific Inc.
• MaxVision Biosciences Inc.
• Olympus Corporation
• AESKU GROUP GmbH
• Danaher Corporation
• Bio-Rad Laboratories Inc.
• Merck KGaA
• Bruker Corporation
• Sino Biological Inc.
• Enzo Biochem Inc.
• Dikinson and Company
• Cell Signaling Technology Inc.
• Bio Tek Instruments, Inc.
• Zyagen
• BioLegend Inc.
• others

Market Segmentation

• By Type
  • Direct immunofluorescence (Primary)
  • Indirect immunofluorescence (Secondary)
• By Product
  • Antibodies
  • reagents
  • kits
  • instruments
  • consumables and accessories
• By Application
  • Autoimmune Diseases
  • Neurological Diseases
  • Clinical Research and Diagnostics
  • Cardiovascular Diseases
  • Cancer
• By End user
  • Pharmaceutical and Biotechnology Companies 
  • Contract Research Organizations
  • Hospitals and Diagnostic Centers

• By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Click Here to View Full Report Table of Contents

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39765

You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333

Blog: https://www.novaoneadvisor.com/

Blog: https://qyresearchmedical.com/